SCHEMBL24257797

SCHEMBL24257797

CCOC(=O)CNC(=O)c1ncc(-c2cnn(C(C)C)c2)c(C)c1O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
ALDH1A1 P00352 6/20 0.39
HSD17B10 Q99714 2/20 0.39
LMNA P02545 2/20 0.39
HPGD P15428 2/20 0.39
EGLN1 Q9GZT9 3/20 0.36
VEGFA P15692 2/20 0.36
FLT1 P17948 2/20 0.36
EGLN3 Q9H6Z9 2/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
MAPT P10636 1/20 0.36
GAA P10253 2/20 0.35
KDM4E B2RXH2 1/20 0.34
ACHE P22303 1/20 0.34
RAB9A P51151 3/20 0.34
NPC1 O15118 2/20 0.34
JAK2 O60674 2/20 0.33
FLT3 P36888 2/20 0.33
JAK1 P23458 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257670 0.88 EGLN1 (0.43) HSP90AA1HSP90AB1EGLN1VEGFAFLT1
SCHEMBL24257770 0.86 ALDH1A1 (0.39) HSP90AA1HSP90AB1ALDH1A1HSD17B10LMNA
SCHEMBL24257538 0.83 KMT2A (0.39) HSP90AA1HSP90AB1ALDH1A1HSD17B10LMNA
SCHEMBL24257699 0.82 HPGD (0.44) ALDH1A1HSD17B10LMNAHPGDEGLN1
SCHEMBL24257828 0.80 EGLN1 (0.43) ALDH1A1HSD17B10LMNAHPGDEGLN1
SCHEMBL24257767 0.80 NPC1 (0.41) ALDH1A1HSD17B10LMNAHPGDEGLN1
SCHEMBL26259968 0.79 ALDH1A1 (0.42) ALDH1A1HSD17B10LMNAHPGDEGLN1
SCHEMBL24257534 0.79 CASP1 (0.49) ALDH1A1HSD17B10LMNAHPGDEGLN1
SCHEMBL30453195 0.79 CASP1 (0.49) ALDH1A1HSD17B10LMNAHPGDEGLN1
SCHEMBL24257746 0.79 ABL1 (0.40) ALDH1A1HSD17B10LMNAHPGDFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 HSP90AA1 350/4885HSP90AB1 174/4885ALDH1A1 1362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.